Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide

Archives of Ophthalmology

Volumn 116, Issue 1, 1998, Pages 19-24

  Larsson, Lill Inger ^a   Alm, Albert ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; FLUORESCEIN;

ADULT; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR FORMATION; ARTICLE; BICARBONATE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; METABOLIC ACIDOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031885175     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.1.19     Document Type: Article

References (41)

1. Kinsey VE. Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eye. Arch Ophthalmol. 1953:50:401-417.
2. Wistrand P. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand. 1951:24:144-148
3. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol. 1954;37:13-15.
4. Grant WM, Trotter RR. Diamox (acetazolamide) in the treatment of glaucoma. Arch Ophthalmol. 1954:51:735-739.
5. Breinin GM, Görtz H. Carbonic anhydrase inhibitor acetazolamide (Diamox): a new approach to the therapy of glaucoma. Arch Ophthalmol. 1954;52:333-348.
6. Lichter PR, Newman LP, Wheeler NC, Beau OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978:85:495-502.
7. Friedman Z, Alien RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985:103:963-966.
8. Foss RH. Local application of Diamox: an experimental study of its effect on the intraocular pressure. Am J Ophthalmol. 1955:39:336-339.
9. Mären TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev. 1967;47:595-781.
10. Maren TH, Jankowska L, Sanyal G, Edelhauser HF. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983:36:457-480.
11. Stein A, Pinke R, Krupin T, et al. The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits. Am J Ophthalmol. 1983:95:222-228.
12. Ponticello GS, Freedman MB, Habecker CN, et al. Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors. JMedChem. 1987:591-597.
13. Kitazawa Y, Azuma I, Iwata K, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma. 1994:3:275-279.
14. Lippa EA, Carlson L-E, Ehinger B, etal. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992; 110:495-499.
15. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 1991:98:308-313.
16. Gunning FP, Grève EL, Bron AM, et al. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefes Arch Clin Exp Ophthalmol. 1993:231:384-388.
17. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993:111:1343-1350.
18. Yamazaki Y, Miyamoto S, Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophtha/mol. 1994;38:92-96.
19. The MK-507 Clinical Study Group. Long-term glaucoma treatment with MK507, dorzolamide, a topical carbonic anhydrase inhibitor. J Glaucoma. 1995;4: 6-10.
20. Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group. A double-masked, randomized 1 -year study comparing dorzolamide (Trusopt), timolol. and betaxolol. Arch Ophtha/mol. 1995:113:1009-1016.
21. Wang R-F, Serie JB. Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991:109:1297-1299.
22. Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF. 6-amino-2-benzothiazole-sulfonamide: the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology. 1988; 95:772-777.
23. Maus TL, Larsson L-l, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49.
24. Baldwin JJ, Ponticello GS, Anderson PS, et al. Thienothiopyran-2sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. JMedChem. 1989:32:2510-2513.
25. Becker B. Carbonic anhydrase and the formation of aqueous humor: the Friedenwald Memorial Lecture. Am J Ophthalmol. 1955:47:342-361.
26. Matsui H, Murakami M, Wynns GC, et al. Membrane carbonic anhydrase (IV) and ciliary epithelium carbonic anhydrase activity is present in the basolateral membranes of the non-pigmented ciliary epithelium of rabbit eyes. ExpEye Res. 1996:62:409-417.
27. Brubaker RF. Measurement of aqueous flow by fluorophotometry. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St Louis, Mo; CV Mosby Co: 1989; 1:337-344.
28. Fagerlund C, Hartvig P, Lindstrom P. Extractive alkylation of sulphonamide diuretics and their determination by electron-capture gas chormatography. JChromatogr A. 1979;168:107-116.
29. Berry DJ. The determination of acetazolamide in human plasma by reversed phase HPLC. 12th International Symposium on Column LiQuid Chromatography, 1988. Abstract #TU-P-282.
30. Brubaker RF. Flow of aqueous humor in humans: the Friedenwald Lecture. Invest Ophthalmol Vis Sei. 1991 ;32:3145-3166.
31. Dixon WJ, Massey JF Jr. Introduction to Statistical Analysis. New York, NY: McGraw-Hill Book Co; 1969:516.
32. Derick RJ. Glaucoma therapy: carbonic anhydrase inhibitors. In: Mauger TF, Craig EL, eds. Havener's Ocular Pharmacology. 6th ed. St Louis, Mo: Mosby-Year Book Inc; 1994:172-200.
33. Aim A, Berggren L, Hartvig P, Roosdorp M. Monitoring acetazolamide treatment. Acta Ophthalmol. 1982:60:24-34.
34. Wistrand PJ, Garg LC. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophtha/mol Vis Set. 1979;18:802-806.
35. Ridderstrale Y, Wistrand PJ, Brechue WF. Membrane-associated CA activity in the eye of the CA ll-deficient mouse. Invest Ophthalmol Vis Sei. 1994:35:25772584.
36. Lönnerholm G, Wistrand PJ. Membrane-bound carbonic anhydrase CA IV in the human kidney. Acta Physiol Scand. 1991:141:231-234.
37. Maren TH. Current status of membrane-bound carbonic anhydrase. Ann N YAcad Sei. 1980:341:246-258.
38. Brechue WF, Kinne-Saffran E, Kinne RKH, Mareri TH. Localization and activity of renal carbonic anhydrase (CA) in CA-II deficient mice. Biochim BiophysActa. 1991;1066:201-207.
39. Maren TH. Basic sciences in clinical glaucoma: the development of topical carbonic anhydrase inhibitors. J Glaucoma. 1995;4:49-62.
40. Langham ME, Lee PM. Action of Diamox and ammonium chloride on formation of aqueous humor. BrJ Ophthalmol. 1957;41:65-92.
41. Krupin T, Gestrick CJ, Bass J, Podos SM, Becker B. Acidosis, alkalosis, and aqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sei. 1977;16:9971001.